Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

Junna Oba, Takeshi Nakahara, Sayaka Hayashida, Makiko Kido, Lining Xie, Masakazu Takahara, Hiroshi Uchi, Shogo Miyazaki, Takeru Abe, Akihito Hagihara, Yoichi Moroi, Masutaka Furue

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

Original languageEnglish
Pages (from-to)1152-1160
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume65
Issue number6
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Melanoma
Neoplasms
Survival
Tumor-Infiltrating Lymphocytes
Pigmented Nevus
Nevus
Tumor Biomarkers
Proportional Hazards Models
Paraffin
Sample Size
Formaldehyde
Multivariate Analysis
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. / Oba, Junna; Nakahara, Takeshi; Hayashida, Sayaka; Kido, Makiko; Xie, Lining; Takahara, Masakazu; Uchi, Hiroshi; Miyazaki, Shogo; Abe, Takeru; Hagihara, Akihito; Moroi, Yoichi; Furue, Masutaka.

In: Journal of the American Academy of Dermatology, Vol. 65, No. 6, 01.12.2011, p. 1152-1160.

Research output: Contribution to journalArticle

Oba, Junna ; Nakahara, Takeshi ; Hayashida, Sayaka ; Kido, Makiko ; Xie, Lining ; Takahara, Masakazu ; Uchi, Hiroshi ; Miyazaki, Shogo ; Abe, Takeru ; Hagihara, Akihito ; Moroi, Yoichi ; Furue, Masutaka. / Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. In: Journal of the American Academy of Dermatology. 2011 ; Vol. 65, No. 6. pp. 1152-1160.
@article{144aab0694204ea3b8e6af1cc0bba3d9,
title = "Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma",
abstract = "Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53{\%}) of primary MM expressed CD10, compared with 15 of 20 cases (75{\%}) of metastatic MM and only 4 of 40 cases (10{\%}) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.",
author = "Junna Oba and Takeshi Nakahara and Sayaka Hayashida and Makiko Kido and Lining Xie and Masakazu Takahara and Hiroshi Uchi and Shogo Miyazaki and Takeru Abe and Akihito Hagihara and Yoichi Moroi and Masutaka Furue",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.jaad.2010.10.019",
language = "English",
volume = "65",
pages = "1152--1160",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

AU - Oba, Junna

AU - Nakahara, Takeshi

AU - Hayashida, Sayaka

AU - Kido, Makiko

AU - Xie, Lining

AU - Takahara, Masakazu

AU - Uchi, Hiroshi

AU - Miyazaki, Shogo

AU - Abe, Takeru

AU - Hagihara, Akihito

AU - Moroi, Yoichi

AU - Furue, Masutaka

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

AB - Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

UR - http://www.scopus.com/inward/record.url?scp=81155131257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155131257&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.10.019

DO - 10.1016/j.jaad.2010.10.019

M3 - Article

C2 - 21700362

AN - SCOPUS:81155131257

VL - 65

SP - 1152

EP - 1160

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -